General Information of Drug (ID: DMPT74G)

Drug Name
NS-638 Drug Info
Synonyms
150493-34-8; NS-638; NS638; 2-Amino-1-(4-chlorobenzyl)-5-trifluoromethylbenzimidazole; 1-[(4-chlorophenyl)methyl]-5-(trifluoromethyl)benzimidazol-2-amine; 1H-Benzimidazol-2-amine,1-[(4-chlorophenyl)methyl]-5-(trifluoromethyl)-; NS 638; GXQCVUZORDAARJ-UHFFFAOYSA-N; ACMC-20n5zm; AC1L2SIQ; SCHEMBL3083259; ZINC5752; CTK4C6667; DTXSID10164561; MolPort-046-033-572; BCP20747; AKOS032947353; 1-((4-Chlorophenyl)methyl)-5-(trifluoromethyl)-1H-benzimidazol-2-amine; CS-6337; KB-227320; HY-101428
Indication
Disease Entry ICD 11 Status REF
Cerebrovascular ischaemia 8B1Z Terminated [1]
Cross-matching ID
PubChem CID
127722
CAS Number
CAS 150493-34-8
TTD Drug ID
DMPT74G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nicardipine DMCDYW7 High blood pressure BA00 Approved [3]
Clevidipine butyrate DMW4M97 Hypertension BA00-BA04 Approved [4]
Nisoldipine DM7ISKJ Hypertension BA00-BA04 Approved [5]
Felodipine DMOSW35 Hypertension BA00-BA04 Approved [6]
Nimodipine DMQ0RKZ Cerebral vasospasm BA85.Z Approved [7]
Bepridil DM0RKS4 Chronic/stable angina BA40.1 Approved [8]
Isradipine DMA5XGH Hypertension BA00-BA04 Approved [8]
DIPROTEVERINE HYDROCHLORIDE DMG8U6M Angina pectoris BA40 Phase 3 [9]
ATI-2042 DMWP59B Atrial fibrillation BC81.3 Phase 2 [10]
HBI-3000 DM74ZKN Heart arrhythmia BC65 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium channel unspecific (CaC) TT5HONZ NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005354)
2 Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. Neurol Res. 1995 Oct;17(5):353-60.
3 Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
4 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
5 RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
6 Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
7 Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.